Plain-English translation of NCT05957757 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two medications used together— and —can effectively treat a type of bladder cancer that has come back after previous treatment in patients who are not candidates for or prefer not to have bladder removal surgery. is a targeted therapy, and is an immunotherapy that helps your immune system fight cancer. The goal is to stop the cancer from progressing while allowing you to keep your bladder.
About 30–40% of patients with this type of bladder cancer do not respond well to standard immune therapy (called BCG treatment), and the current surgical option to remove the bladder carries serious risks and side effects that many patients want to avoid. This trial exists because there is a need for effective non-surgical treatment options for people in this situation.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the two medications on a regular schedule: every two weeks and every three weeks. You will have baseline procedures including cystoscopy (a camera exam of your bladder) to document your disease, and you will be monitored closely with follow-up visits, imaging, and urine tests to assess how well the treatment is working and to watch for side effects. The trial is enrolling approximately 20 participants total.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China